Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Hodgkin Lymphoma: early-phase trial registry
58 of 107 indexed Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #120 of 28,707 conditions by registered trial count.
107 US clinical trials · 58 currently recruiting · #120 of 28,707 conditions by registered trial count
Non-Hodgkin Lymphoma: 107 US clinical trials tracked, 58 recruiting.
Non-Hodgkin Lymphoma is the subject of 107 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 7 of these trials.
Enrollment posture brief
Registry condition non-hodgkin-lymphoma
OPEN 58 | RECR 54% | LATE 6 | EARLY 86 | RANK #120 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Bulimia Nervosa (54% recruiting · 24 trials)
Non-Hodgkin Lymphoma lists 58 open slots (54% of 107 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Hodgkin Lymphoma is recruiting above its size-band peers.
58 of 107 indexed trials (54.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Hodgkin Lymphoma trials is spread across many organizations.
Baylor College of Medicine accounts for 7 of 107 trials (6.5%). 77 distinct sponsors appear on at least one study for this condition label.
-
Most Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 107 trials that report a genuine target (sentinel values excluded). 68 of those (63.6%) plan for fewer than 100 participants.
-
Non-Hodgkin Lymphoma research is mostly interventional.
98 interventional and 9 observational studies make up this index (91.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
107 total, page 2 of 3
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT02508038
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma
NCT06343311
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Taylor Brooks
NCT06447376
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
Stanford University
NCT05794958
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Mitchell Cairo
NCT04099966
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
University of Colorado, Denver
NCT05425992
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT05990465
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
National Cancer Institute (NCI)
NCT00039676
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
NCT00840047
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
City of Hope Medical Center
NCT04537871
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Genentech
NCT05207670
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04459416
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
NCT05171647
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma
NCT02180711
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Werewolf Therapeutics
NCT06939283
DS-3201b in Participants With Lymphomas
Daiichi Sankyo Co.
NCT02732275
huCART19-IL18 in CD19+ Cancers
University of Pennsylvania
NCT04684563
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics
NCT04673617
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT03842696
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Washington University School of Medicine
NCT05044039
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Baylor College of Medicine
NCT02287311
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Baylor College of Medicine
NCT01333046
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Benjamin Tomlinson
NCT03434769
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
University of Chicago
NCT05019976
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
NCT03713580
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
David Wald
NCT05400109
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05574114
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Benjamin Tomlinson
NCT04732845
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
NCT05206357
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Sana Biotechnology
NCT05878184
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT01494103
A Rollover Study of CC-122
Bristol-Myers Squibb
NCT05688475
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Abramson Cancer Center at Penn Medicine
NCT04827862
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Wake Forest University Health Sciences
NCT03935282
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
AbbVie
NCT01328626
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Children's Oncology Group
NCT01000753
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology
NCT03013218
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
NCT03467373
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
MorphoSys
NCT01685008
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Baylor College of Medicine
NCT00062868
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT01947140
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT03755414
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT05169658
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
NCT03019666
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
MedImmune
NCT01030536
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 67 |
| Phase 2 | 19 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Hodgkin Lymphoma page
107 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Hodgkin Lymphoma condition card totals 107 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.